Medtronic's growth strategies, dividend stability, and innovation focus amidst debt concerns and market risks. Click here to ...

Boston Scientific has surged 40.5% in the past year, outpacing both its industry and the S&P 500. The WATCHMAN FLX and ...

The emergence of generative artificial intelligence (AI) indicates a paradigm shift in military research and application, ...

Boston Scientific reached an all-time high of $107.2 per share, buoyed by a 40.16% annual gain and stellar financials.

Thermo Fisher Scientific’s Accelerator™ Drug Development solutions, which integrate services for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) ...

Boston Scientific BSX has raised its full-year 2025 guidance following robust first-quarter results and continued momentum ...

Leventhal & Reif: Saving the Bay State’s innovation economy The authors write that Massachusetts’ life sciences sector alone supports 143,000 jobs. (Photo Metro Creative Services) ...

Investors in Boston Scientific Corp. (Symbol: BSX) saw new options become available today, for the February 2026 expiration. One of the key data points that goes into the price an option buyer is ...

More information: Henry Dao et al, Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development, Drug Discovery Today ...

With NutriSelect’s consumer-facing app launching soon, the SAB will play an instrumental role in ensuring its AI engine and recommendations meet rigorous scientific standards. Visit NutriSelect to ...

Boston Scientific’s Operating Cash Flow (OCF) for the same period was $3.8 billion, indicating a good OCF margin of 21.7% compared to the S&P 500’s 14.9%.

Boston Scientific Corporation’s relative price strength rank of 70 means that its weighted four-quarter return ranks in the 70 th percentile of all U.S.-listed stocks. This score reflects the ...